May 17, 2020

CGT Catapult signs contract to utilise TrakCel supply chain management platform

CGT
Catapult
medical
testing
James Henderson
3 min
TrakCel has been awarded a contract to provide its supply chain platform to CGT Catapult
The Cell and Gene Therapy Catapult (CGT Catapult) has signed a partnership agreement with UK-headquartered company TrakCel to incorporate its needle-to...

The Cell and Gene Therapy Catapult (CGT Catapult) has signed a partnership agreement with UK-headquartered company TrakCel to incorporate its needle-to-needle supply chain management platform into the CGT Catapult’s large-scale cell and gene therapy manufacturing centre. 

The 7,200m2 manufacturing centre provides a state-of-the-art GMP facility and support infrastructure to enable collaborators to carry out the large-scale manufacture of cell and gene therapies as they progress towards commercial supply.

Establishing a robust supply chain from the scheduled collection of patient samples, tracking throughout the manufacturing process and delivery back to that same patient is a complex process.

As a result, it is becoming increasingly critical for manufacturers as the patient numbers involved in late stage clinical trials and future commercial supply increase.

The partnership will allow CGT Catapult collaborators to plug into an established software solution that will be able to track cell therapies across the whole supply chain, completely integrated within its validated systems at the manufacturing centre and associated cryo-storage and logistics facilities.

“We are pleased to provide our partners at the manufacturing centre with complimentary tracking technology, such as the TrakCel Cellular Orchestration Platform, as we work to not only offer GMP manufacturing support in Stevenage but also ease our collaborator’s access to a fully developed, high-quality global supply chain,” said Keith Thompson, Chief Executive Officer, Cell and Gene Therapy Catapult.

SEE ALSO:

The TrakCel technology will link, in addition to the manufacturing centre, with Thermo Fisher Scientific’s new Fisher Bioservices CryoHubSM, being built adjacent to the manufacturing centre warehouse.

The Cryohub will provide services for distribution of patient sample collection sets, cGMP cryo-storage of cell and gene therapies and also cryo-logistics for supply of these therapies throughout the UK and beyond, with Europe’s busiest airport (Heathrow) just an hour away.

Finally, the TrakCel technology will help further establish the Stevenage Bioscience Catalyst, where these services are located, as an emerging cell and gene therapy cluster not just for the UK but globally by offering another world first in life sciences innovation.

Thompson elaborated: “This integration of GMP manufacturing, cryo-storage and logistics support within a complete end to end supply chain management solution is something which has not been done before and is critical to enabling commercial supply of cell and gene therapies in the UK.”

CGT Catapult specifically selected TrakCel as it has an established product installed and validated at sponsors, clinical sites, CMOs and logistic partners across North America and Europe. 

To minimise risks to product quality and patient safety it is essential that the supply chain is tracked and controlled both before and after the manufacturing process.  

Share article

Jul 13, 2021

5 minutes with: Ivalua’s Sundar Kamak

Ivalua
supplychain
Manufacturing
Procurement
2 min
Ivalua
Procurement and manufacturing veteran Sundar Kamak, Head of Manufacturing Solutions, Ivalua weighs in on challenges and opportunities in the industry

Who are you? 

My name is Sundar Kamak, I’m Head of Manufacturing Solutions at Ivalua. I’ve been with the company for around two years now, and I’m responsible for our industry solutions and our pre-sales team. Before joining Ivalua I spent almost 20 years in the source-to-pay procurement space, working for a number of providers. But I got my career started in manufacturing and supply chain, specifically in automotive and aerospace.

And what is currently taking up the majority of your professional time?
 

The last year I've been focused in helping organisations put together a digital transformation strategy, especially manufacturing companies, so they can continue to address some of the challenges they face due to the COVID pandemic. 

The traditional approach of engineers designing their latest product then procurement going off to source no longer works


What are the biggest challenges facing your corner of supply chain? 
 

We have a lot of clients coming from different backgrounds - aerospace, high-tech, automotive - and they’re feeling the pressure and the crunch. There’s a lack of product, lack of material availability, lack of resources, labour shortages. So, I work with the leadership in these organisations, try to understand what problems they're looking to solve and come back with Ivalua solutions that can help them address some of these challenges.

Where do the biggest opportunities lie? 
 

If we look at manufacturing, it all comes back to procurement and supply chain being involved sooner in the process. The traditional approach of engineers designing their latest product then procurement going off to source no longer works. It’s important to treat suppliers like partners, which means you build trust, so they can participate very early on in the product design and product development process. It’s not done consistently in the manufacturing sector, but it will be key. 
 

Share article